Anzeige
❌
Mehr »
Sonntag, 04.10.2026 - Börsentäglich über 12.000 News
Die Lizenz, über die niemand spricht, und warum Wettbewerber keine bekommen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
CE

WKN: A422GY | ISIN: US72941H8060 | Ticker-Symbol: XMP1
Frankfurt
02.10.26 | 08:01
1,484 Euro
-4,99 % -0,078
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CERENOME INC Chart 1 Jahr
5-Tage-Chart
CERENOME INC 5-Tage-Chart

Aktuelle News zur CERENOME Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCERENOME, INC. - 8-K, Current Report12
CERENOME Aktie jetzt für 0€ handeln
MiCerenome, Inc.: Cerenome Expects $1.55 Million in CNSide Third Quarter Gross Billings163Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30...
► Artikel lesen
25.09.Cerenome, Inc.: Cerenome to Hold CNSide Business Update Call on September 30, 20262
22.09.CNSide Diagnostics signs agreement with Blue Cross Michigan1
22.09.Cerenome, Inc.: Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide Contracted Coverage to Approximately 158 Million Covered Lives3
16.09.Cerenome Appoints Samantha Fowlkes As Vice President And Head Of Commercial Sales For CNSide Diagnostics1
16.09.Cerenome beruft Samantha Fowlkes zur Vertriebsleiterin von CNSide Diagnostics4
16.09.Cerenome appoints Samantha Fowlkes as commercial sales head3
16.09.Cerenome, Inc.: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division440HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announces the appointment of Samantha...
► Artikel lesen
10.09.CERENOME, INC. - 8-K, Current Report10
10.09.Cerenome, Inc.: Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment495Capital will support continued CNSide commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028...
► Artikel lesen
17.08.Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlook22
14.08.Cerenome, Inc.: Cerenome Reports Second Quarter 2026 Financial Results and Business Update530HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics...
► Artikel lesen
13.08.Cerenome, Inc.: Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide Contracted Coverage to Over 150 Million Covered Lives23
06.08.Cerenome subsidiary selects XiFin for diagnostic billing services11
04.08.CERENOME, INC. - 8-K, Current Report32
03.08.Plus Therapeutics Rebrands with Launch of Cerenome2
31.07.Plus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology Company705HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective...
► Artikel lesen
21.07.CNSide Diagnostics signs coverage deal with Medical Mutual14
21.07.Plus Therapeutics Inc.: Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer439HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed...
► Artikel lesen
1 2 3 4 Weiter >>
79 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1